| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/10/2002 | US6448248 Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists |
| 09/10/2002 | US6448241 Thiazolobenzoheterocycles, their preparation and medicaments containing them |
| 09/10/2002 | US6448239 Porphyrin ring metallic complexes that are effective peroxynitrite decomposition catalysts for treatment of diseases involving the accumulation of this oxidant, such as altzeimer's disease |
| 09/10/2002 | US6448236 Functional agonists of the human adenosine a2a receptor and may be used as, for example, anti-inflammatory agents in the treatment of repiratory diseases |
| 09/10/2002 | US6448221 By administering an adipocyte complement related protein to reduce platelet aggregation |
| 09/10/2002 | US6448083 Contacting a mammalian cell with filamentous phage particles presenting a ligand on their surfaces, wherein a vector within the phage encodes a gene product under control of a promoter |
| 09/10/2002 | US6448054 Locally administering to a specific site a fugetactic agent in an amount effective to repel immune cells |
| 09/10/2002 | US6448036 ribB |
| 09/10/2002 | US6448021 Cc-chemokine receptor 2 (ccr2) bound by an antibody or functional fragment to block binding of a ligand |
| 09/10/2002 | US6448019 Inhibit vascular smooth muscle cell activation and/or proliferation or enhance vascular endothelial cell activation and/or proliferation or activate estrogen responsive genes in vascular cells. vasoprotective agents are vasospecific, |
| 09/10/2002 | US6448011 Isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant adrenergic receptor genes. |
| 09/10/2002 | US6447819 Water-soluble complex of an extract of Ginkgo biloba, process for the preparation thereof and composition comprising the same |
| 09/10/2002 | US6447814 Plant extracts used for prevention of cardiovascular disorders, obtained by solvent extraction, heating, filtration and condensation, then encapsulation to form particles; side effect reduction |
| 09/10/2002 | CA2198562C Method of treating conditions with estrogen agonists |
| 09/06/2002 | WO2002068676A2 METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING |
| 09/06/2002 | WO2002068642A1 A novel polypeptide compose substance for promoting blood and blood vessel cell growth |
| 09/06/2002 | WO2002068640A1 CELL PROLIFERATION FACTOR Fwa267 |
| 09/06/2002 | WO2002068639A1 CELL PROLIFERATION FACTOR Fwap10576 |
| 09/06/2002 | WO2002068617A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/06/2002 | WO2002068476A2 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 09/06/2002 | WO2002068461A2 Heterocarpine, a human ghrh-binding protein |
| 09/06/2002 | WO2002068457A2 Antiangiogenic peptides derived from endostatin |
| 09/06/2002 | WO2002068440A1 Glycopyranosyloxypyrazole derivatives and medicinal use thereof |
| 09/06/2002 | WO2002068439A1 Glycopyranosyloxypyrazole derivatives and medicinal use thereof |
| 09/06/2002 | WO2002068425A1 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists |
| 09/06/2002 | WO2002068419A1 Pyridopyrimidine or naphthyridine derivative |
| 09/06/2002 | WO2002068415A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/06/2002 | WO2002068414A2 Analogs of thalidomide as potential angiogenesis inhibitors |
| 09/06/2002 | WO2002068410A1 Substituted pyrimidinone derivatives as ligands of integrin receptors |
| 09/06/2002 | WO2002068406A2 Substituted amine derivatives and their use for the treatment of angiogenesis |
| 09/06/2002 | WO2002068399A1 Aryl carbamate derivatives, preparation and use thereof |
| 09/06/2002 | WO2002068393A1 Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors |
| 09/06/2002 | WO2002068390A1 Diamides which inhibit tryptase and factor xa activity |
| 09/06/2002 | WO2002068388A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 09/06/2002 | WO2002068377A1 Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells |
| 09/06/2002 | WO2002068015A2 Modular infusion device and method |
| 09/06/2002 | WO2002067976A1 Novel ischemia/reperfusion injury inhibitors |
| 09/06/2002 | WO2002067971A2 Use of endostatin in the treatment of ocular neovascularization |
| 09/06/2002 | WO2002067970A1 TRYPTOPHANYL-tRNA SYNTHETASE DERIVED POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| 09/06/2002 | WO2002067963A1 Compositions for lowering serum cholesterol level |
| 09/06/2002 | WO2002067961A2 Therapeutic uses of herbal compositions |
| 09/06/2002 | WO2002067960A1 Herbal compositions useful as chemopreventive and therapeutic agents |
| 09/06/2002 | WO2002067955A2 A process for the manufacture of a herbal composition comprising a matrine |
| 09/06/2002 | WO2002067953A2 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia |
| 09/06/2002 | WO2002067950A1 Vascular regeneration promoters |
| 09/06/2002 | WO2002067949A1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating cardio-cerebrovascular anoxemia |
| 09/06/2002 | WO2002067939A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/06/2002 | WO2002067938A2 Treating or reducing the risk of cardiovascular disease |
| 09/06/2002 | WO2002067935A1 A stable pharmaceutical formulation comprising torsemide modification ii |
| 09/06/2002 | WO2002067925A1 Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| 09/06/2002 | WO2002067919A1 Il-8 receptor antagonists |
| 09/06/2002 | WO2002067917A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | WO2002067906A1 Coating and binding agent for pharmaceutical formulations with improved storage stability |
| 09/06/2002 | WO2002067870A2 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease |
| 09/06/2002 | WO2002067861A2 Oncolytic adenoviral vectors |
| 09/06/2002 | WO2002067857A2 Modified annexin proteins and methods for preventing thrombosis |
| 09/06/2002 | WO2002067851A2 Method for treating fibrotic diseases or other indications iiic |
| 09/06/2002 | WO2002067688A1 Noninvasive measurements of chemical substances |
| 09/06/2002 | WO2002053092A3 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| 09/06/2002 | WO2002047712A3 Peptide yy and peptide yy agonists for treatment of metabolic disorders |
| 09/06/2002 | WO2002046216A3 Human sprouty-4 polypeptide |
| 09/06/2002 | WO2002046183A3 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 09/06/2002 | WO2002043659A3 Composition containing statins and calcium for improved cardiovascular health |
| 09/06/2002 | WO2002043648A8 Compounds active at the glucocorticoid receptor ii |
| 09/06/2002 | WO2002041882A3 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 09/06/2002 | WO2002040517A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2002040037A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2002038563A3 Condensed pyrazindione derivatives as pde inhibitors |
| 09/06/2002 | WO2002036792A3 Dna expression vectors |
| 09/06/2002 | WO2002036771A3 Imaging, diagnosis and treatment of disease |
| 09/06/2002 | WO2002016574A3 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type |
| 09/06/2002 | WO2002012250A3 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
| 09/06/2002 | WO2002010217A3 Endothelial cell expression patterns |
| 09/06/2002 | WO2002002629A3 Grf2-binding proteins and applications thereof |
| 09/06/2002 | WO2001095946A3 Combination product for carrying out a cytotoxic treatment in a mammal |
| 09/06/2002 | WO2001095937A3 Phytoestrogenic isoflavone compositions |
| 09/06/2002 | WO2001094612A3 Method for identifying medically valuable active substances |
| 09/06/2002 | WO2001092565A3 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription |
| 09/06/2002 | WO2001092479A3 Method to determine the differentiation potential of a target cell |
| 09/06/2002 | WO2001064738A3 Heparin-binding amino acid sequences derived from human proteins facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 09/06/2002 | WO2001024681A9 Alterations in the long qt syndrome genes kvlqt1 and scn5a and methods for detecting same |
| 09/06/2002 | WO2001014581A9 Hdac4 and hdac5 in the regulation of cardiac gene expression |
| 09/06/2002 | CA2617312A1 Noninvasive measurement of chemical substances |
| 09/06/2002 | CA2617004A1 Noninvasive measurements of chemical substances |
| 09/06/2002 | CA2439472A1 Methods and compositions for modifying apolipoprotein b mrna editing |
| 09/06/2002 | CA2439265A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/06/2002 | CA2439261A1 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease |
| 09/06/2002 | CA2439115A1 Novel oncolytic adenoviral vectors |
| 09/06/2002 | CA2438828A1 Aryl carbamate derivatives, preparation and use thereof |
| 09/06/2002 | CA2438784A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | CA2438273A1 Tryptophanyl-trna synthetase derived polypeptides useful for the regulation of angiogenesis |
| 09/06/2002 | CA2438238A1 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 09/06/2002 | CA2438063A1 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia |
| 09/06/2002 | CA2437516A1 Heterocarpine, a human ghrh-binding protein |
| 09/06/2002 | CA2437114A1 Diamides which inhibit tryptase and factor xa activity |
| 09/06/2002 | CA2434690A1 Proteins, polynucleotides encoding them and methods of using the same |
| 09/06/2002 | CA2434666A1 Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors |
| 09/06/2002 | CA2433425A1 Method for treating fibrotic diseases or other indications iiic |
| 09/06/2002 | CA2432029A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/06/2002 | CA2410802A1 A stable pharmaceutical formulation comprising torsemide modification ii |